The company Laboratorios AICA, part of the Biotechnological and Pharmaceutical Industries Group (Biocubafarma), announced the resumption of cytostatic medication production following the completion of an investment process aimed at strengthening regulatory standards at its plant and equipment.

The entity specified from its Facebook profile that the progress guarantees compliance with international regulations and directly impacts the availability of cytostatics within the national basic drug list, thereby ensuring more timely access for patients requiring these treatments.

Authorities such as Deputy Prime Minister Eduardo Martínez Díaz and Biocubafarma president Mayda Mauri Pérez verified the quality of the investment execution during a recent visit, in which they highlighted compliance with Good Manufacturing Practices.

The project included the recovery of production lines, research and development, as well as distribution logistics, with the commitment to resume deliveries to the health system despite the impact of the economic, commercial, and financial blockade.